GeoVax Labs (GOVX) 10-Q 9 Nov 22 2022 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2022	Nov. 09, 2022
Document Information [Line Items]
Entity Central Index Key	0000832489
Entity Registrant Name	GeoVax Labs, Inc.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Transition Report	false
Entity File Number	001-39563
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	87-0455038
Entity Address, Address Line One	1900 Lake Park Drive, Suite 380
Entity Address, City or Town	Smyrna
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	30080
City Area Code	678
Local Phone Number	384-7220
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		26,334,953
Warrants to Purchase Common Stock [Member]
Document Information [Line Items]
Title of 12(b) Security	Warrants to Purchase Common Stock
Trading Symbol	GOVXW
Security Exchange Name	NASDAQ
Common Stock [Member]
Document Information [Line Items]
Title of 12(b) Security	Common Stock $0.001 par value
Trading Symbol	GOVX
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
ASSETS
Cash and cash equivalents	$ 34,676,968	$ 11,423,870
Grant funds receivable		49,006
Total prepaid expenses	1,460,207	156,240
Total current assets	36,137,175	11,629,116
Property and equipment, net	248,983	156,938
Other assets	2,184,286	11,010
Total assets	38,570,444	11,797,064
Current liabilities:
Accounts payable	1,079,421	2,057,534
Accrued expenses	3,709,984	3,377,826
Total current liabilities	4,789,405	5,435,360
Other liabilities	2,000,000	2,000,000
Total liabilities	6,789,405	7,435,360
Commitments (Note 4)
Stockholders’ equity:
Common stock, $.001 par value: Authorized shares – 600,000,000 Issued and outstanding shares – 9,449,025 and 6,381,541 at March 31, 2022 and December 31, 2021, respectively	26,335	6,382
Additional paid-in capital	104,767,918	68,731,220
Accumulated deficit	(73,013,214)	(64,375,898)
Total stockholders’ equity	31,781,039	4,361,704
Total liabilities and stockholders’ equity	$ 38,570,444	$ 11,797,064

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2022	Dec. 31, 2021
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized (in shares)	600,000,000	600,000,000
Common stock, issued (in shares)	26,334,953	6,381,541
Common stock, outstanding (in shares)	26,334,953	6,381,541

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Grant and collaboration revenue	$ 0	$ 30,414	$ 81,526	$ 220,539
Operating expenses:
Research and development	2,721,196	1,224,362	5,358,917	2,659,980
General and administrative	1,249,337	757,432	3,363,672	2,562,641
Total operating expenses	3,970,533	1,981,794	8,722,589	5,222,621
Loss from operations	(3,970,533)	(1,951,380)	(8,641,063)	(5,002,082)
Other income (expense):
Interest income	2,431	877	3,747	3,998
Interest expense	0	0	0	(1,286)
Gain on debt extinguishment	0	0	0	172,056
Total other income (expense)	2,431	877	3,747	174,768
Net loss	$ (3,968,102)	$ (1,950,503)	$ (8,637,316)	$ (4,827,314)
Basic and diluted:
Net loss per common share (in dollars per share)	$ (0.17)	$ (0.31)	$ (0.63)	$ (0.80)
Weighted average shares outstanding (in shares)	23,461,665	6,349,297	13,818,315	6,005,032

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2020	100	3,834,095
Balance at Dec. 31, 2020	$ 76,095	$ 3,834	$ 55,294,504	$ (45,805,581)	$ 9,568,852
Common stock issued (in shares)	0	835,900
Issuance of common stock upon warrant exercise	$ 0	$ 836	3,173,320	0	3,174,156
Stock option expense			56,190		56,190
Net loss				(1,562,778)	(1,562,778)
Issuance of common stock for services (in shares)	0	1,472
Issuance of common stock for services	$ 0	$ 1	5,999	0	6,000
Net loss				(1,562,778)	(1,562,778)
Sale of common stock for cash (in shares)	0	1,644,000
Sale of common stock for cash	$ 0	$ 1,644	9,407,276	0	9,408,920
Balance (in shares) at Mar. 31, 2021	100	6,315,467
Balance at Mar. 31, 2021	$ 76,095	$ 6,315	67,937,289	(47,368,359)	20,651,340
Balance (in shares) at Dec. 31, 2020	100	3,834,095
Balance at Dec. 31, 2020	$ 76,095	$ 3,834	55,294,504	(45,805,581)	9,568,852
Net loss					(4,827,314)
Net loss					(4,827,314)
Balance (in shares) at Sep. 30, 2021	0	6,381,541
Balance at Sep. 30, 2021	$ 0	$ 6,382	68,630,363	(50,632,895)	18,003,850
Balance (in shares) at Mar. 31, 2021	100	6,315,467
Balance at Mar. 31, 2021	$ 76,095	$ 6,315	67,937,289	(47,368,359)	20,651,340
Stock option expense	0	0	56,190	0	56,190
Net loss	$ 0	$ 0	0	(1,314,033)	(1,314,033)
Issuance of common stock for services (in shares)	0	12,235
Issuance of common stock for services	$ 0	$ 13	65,828	0	65,841
Net loss	$ 0	$ 0	0	(1,314,033)	(1,314,033)
Repurchase of preferred stock (in shares)	(100)	0
Repurchase of preferred stock	$ (76,095)	$ 0	75,095	0	(1,000)
Balance (in shares) at Jun. 30, 2021	0	6,327,702
Balance at Jun. 30, 2021	$ 0	$ 6,328	68,134,402	(48,682,392)	19,458,338
Common stock issued (in shares)	0	53,839
Issuance of common stock upon warrant exercise	$ 0	$ 54	229,946	0	230,000
Stock option expense	0	0	56,190	0	56,190
Net loss	0	0	0	(1,950,503)	(1,950,503)
Net loss	0	0	0	(1,950,503)	(1,950,503)
Issuance of warrant for technology license	$ 0	$ 0	209,825	0	209,825
Balance (in shares) at Sep. 30, 2021	0	6,381,541
Balance at Sep. 30, 2021	$ 0	$ 6,382	68,630,363	(50,632,895)	18,003,850
Balance (in shares) at Dec. 31, 2021	0	6,381,541
Balance at Dec. 31, 2021	$ 0	$ 6,382	68,731,220	(64,375,898)	4,361,704
Sale of common stock and warrants for cash (in shares)	0	707,484
Sale of common stock and warrants for cash	$ 0	$ 707	9,228,541	0	9,229,248
Common stock issued (in shares)	0	2,360,000
Issuance of common stock upon warrant exercise	$ 0	$ 2,360	(2,336)	0	24
Stock option expense	0	$ 0	190,191	0	190,191
Net loss	0			(2,427,515)	(2,427,515)
Net loss	$ 0			(2,427,515)	(2,427,515)
Balance (in shares) at Mar. 31, 2022		9,449,025
Balance at Mar. 31, 2022		$ 9,449	78,147,616	(66,803,413)	11,353,652
Balance (in shares) at Dec. 31, 2021	0	6,381,541
Balance at Dec. 31, 2021	$ 0	$ 6,382	68,731,220	(64,375,898)	4,361,704
Net loss					(8,637,316)
Net loss					(8,637,316)
Balance (in shares) at Sep. 30, 2022	0	26,334,953
Balance at Sep. 30, 2022	$ 0	$ 26,335	104,767,918	(73,013,214)	31,781,039
Balance (in shares) at Mar. 31, 2022		9,449,025
Balance at Mar. 31, 2022		$ 9,449	78,147,616	(66,803,413)	11,353,652
Sale of common stock and warrants for cash (in shares)		1,050,000
Sale of common stock and warrants for cash		$ 1,050	18,496,896		18,497,946
Common stock issued (in shares)		5,671,214
Issuance of common stock upon warrant exercise		$ 5,671	(5,104)		567
Stock option expense		$ 0	190,191		190,191
Net loss				(2,241,699)	(2,241,699)
Issuance of common stock for services (in shares)		68,500
Issuance of common stock for services		$ 69	71,931		72,000
Net loss				(2,241,699)	(2,241,699)
Balance (in shares) at Jun. 30, 2022		16,238,739
Balance at Jun. 30, 2022		$ 16,239	96,901,530	(69,045,112)	27,872,657
Common stock issued (in shares)	0	10,021,214
Issuance of common stock upon warrant exercise	$ 0	$ 10,021	7,615,522	0	7,625,543
Stock option expense	0	0	190,191	0	190,191
Net loss	$ 0	$ 0	0	(3,968,102)	(3,968,102)
Issuance of common stock for services (in shares)	0	75,000
Issuance of common stock for services	$ 0	$ 75	60,675	0	60,750
Net loss	$ 0	$ 0	0	(3,968,102)	(3,968,102)
Balance (in shares) at Sep. 30, 2022	0	26,334,953
Balance at Sep. 30, 2022	$ 0	$ 26,335	$ 104,767,918	$ (73,013,214)	$ 31,781,039

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities:
Net loss	$ (8,637,316)	$ (4,827,314)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	42,213	26,806
Warrant issued for technology license	0	209,825
Gain on debt extinguishment	0	(172,056)
Changes in assets and liabilities:
Grant funds and other receivables	49,006	182,663
Prepaid expenses and other current assets	(1,251,539)	106,979
Deposits and other assets	(2,173,276)	0
Accounts payable and accrued expenses	(645,955)	(289,477)
Total adjustments	(3,328,656)	314,043
Net cash used in operating activities	(11,965,972)	(4,513,271)
Cash flows from investing activities
Purchase of equipment	(134,258)	(47,718)
Net cash used in investing activities	(134,258)	(47,718)
Cash flows from financing activities:
Net proceeds from sale of common stock and warrants	27,727,194	9,408,920
Net proceeds from warrant exercises	7,626,134	3,404,156
Repurchase of preferred stock	0	(1,000)
Principal repayment of note payable	0	(27,864)
Net cash provided by financing activities	35,353,328	12,784,212
Net increase in cash and cash equivalents	23,253,098	8,223,223
Cash and cash equivalents at beginning of period	11,423,870	9,883,796
Cash and cash equivalents at end of period	34,676,968	18,107,019
Employees and Directors [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	570,573	168,570
Consultants [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	$ 80,322	$ 80,733

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals)	9 Months Ended
	Sep. 30, 2022 USD ($) shares
Paycheck Protection Program CARES Act [Member]
Extinguishment of debt | $	$ 172,056
Stock Purchase Warrants First Issuance [Member]
Common stock issued (in shares)	145,866
Stock purchase warrants exercised (in shares)	188,668

Note 1 - Nature of Business

Note 1 - Nature of Business	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Nature of Operations [Text Block]	1. Nature of Business GeoVax Labs, Inc., headquartered in the Atlanta, Georgia metropolitan area, is a clinical-stage biotechnology company incorporated under the laws of the State of Delaware. GeoVax Labs, Inc. and its wholly owned subsidiary, GeoVax, Inc., a Georgia corporation, are collectively referred to as “GeoVax” or the “Company”. The Company is focused on developing immunotherapies and vaccines against infectious diseases and cancers using novel vector vaccine platforms. GeoVax’s product pipeline includes ongoing human clinical trials for vaccines against COVID- 19

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies We disclosed in Note 2 10 December 31, 2021 nine September 30, 2022, no 10 Basis of Presentation not 10 December 31, 2021. not Our financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. As of the date these financial statements are issued, the Company expects its existing cash and cash equivalents to be sufficient to fund its operations for at least the next twelve may Recent Accounting Pronouncements nine September 30, 2022, no

Note 3 - Balance Sheet Componen

Note 3 - Balance Sheet Components	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Supplemental Balance Sheet Disclosures [Text Block]	3. Balance Sheet Components Prepaid Expenses September 30, 2022 December 31, 2021 Prepaid clinical trial costs (current portion) $ 1,231,337 $ - Prepaid insurance premiums 143,450 123,248 Prepaid rent 13,045 13,045 Other prepaid expenses 72,375 19,947 Total prepaid expenses $ 1,460,207 $ 156,240 Property and Equipment September 30, 2022 December 31, 2021 Equipment and furnishings $ 725,812 $ 591,554 Leasehold improvements 115,605 115,605 Total property and equipment 841,417 707,159 Accumulated depreciation and amortization (592,434 ) (550,221 ) Total property and equipment, net $ 248,983 $ 156,938 Other Assets September 30, 2022 December 31, 2021 Prepaid clinical trial costs (noncurrent portion) $ 2,083,276 $ - Prepaid technology license fees 90,000 - Deposits 11,010 11,010 Total other assets $ 2,184,286 $ 11,010 Accrued Expenses September 30, 2022 December 31, 2021 Accrued technology license fees – current portion $ 3,000,000 $ 3,000,000 Accrued compensation - 269,000 Other accrued expenses 709,984 108,826 Total accrued expenses $ 3,709,984 $ 3,377,826 Other Liabilities September 30, 2022 December 31, 2021

Note 4 - Commitments

Note 4 - Commitments	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Commitments Disclosure [Text Block]	4. Commitments Operating Lease December 31, 2022, three nine September 30, 2022 2021. 2022. License Agreements may Clinical Trial Commitments September 30, 2022, Other Commitments September 30, 2022,

Note 5 - Stockholders' Equity

Note 5 - Stockholders' Equity	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Preferred Stock [Text Block]	5. Stockholders Equity January 2022 January 19, 2022, “Jan 2022 “Jan 2022 March 2022, Jan 2022 Jan 2022 February 10, 2027. May 2022 May 27, 2022, “May 2022 “May 2022 The May 2022 June July August, May 2022 Other Common Stock Transactions May July, Stock Options “2020 may 2020 nine September 30, 2022, 2020 September 30, 2022, Stock Purchase Warrants September 30, 2022. Warrant Description Number of Shares Exercise Price Expiration 2020 Warrants 120,000 $ 1.65 Jun 2025 2020 Unit Warrants 2,396,631 5.00 Sep 2025 2020 Representative Warrants 128,000 5.50 Mar 2024 2021 Representative Warrants 72,000 6.875 Aug 2024 2021 Warrants 100,000 13.00 Sep 2026 Jan 2022 Common Warrants 3,067,484 3.26 Feb 2027 May 2022 Preferred Investment Options 7,500,000 1.65 May 2028 Total Warrants Outstanding at September 30, 2022 13,384,115

Note 6 - Stock-based Compensati

Note 6 - Stock-based Compensation Expense	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	6. Stock-Based Compensation Expense Stock-based compensation expense related to stock options is recognized on a straight-line basis over the requisite service period for the award and is allocated to research and development expense or general and administrative expense based upon the classification of the individual to whom the award is granted. As of September 30, 2022, 1.7 We also have issued shares of restricted common stock to consultants and recognize the related expense over the terms of the related agreements. As of September 30, 2022, The following table summarizes our total stock-based compensation expense for employees, directors and consultants: Three Months Ended Sep. 30, Nine Months Ended Sep. 30, 2022 2021 2022 2021 Stock options: Research and development $ 54,293 $ 21,468 $ 162,878 $ 64,404 General and administrative 135,898 34,722 407,695 104,166 Total stock option expense 190,191 56,190 570,573 168,570 Stock awards (consultants): General and administrative 48,375 29,560 80,322 80,733 Total stock-based compensation expense $ 238,566 $ 85,750 $ 650,895 $ 249,303 During September 2021,

Note 7 - Net Loss Per Share

Note 7 - Net Loss Per Share	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Earnings Per Share [Text Block]	7. Net Loss Per Share Basic and diluted loss per common share are computed based on the weighted average number of common shares outstanding. The Company’s additional potentially dilutive securities, which include stock options and stock purchase warrants, have been excluded from the computation of diluted net loss per share as the effect would be antidilutive. The securities that could potentially dilute basic earnings per share in the future and that have been excluded from the computation of diluted net loss per share totaled 14,346,415 and 3,418,631 shares at September 30, 2022 2021,

Note 8 - Income Taxes

Note 8 - Income Taxes	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Income Tax Disclosure [Text Block]	8. Income Taxes No nine September 30, 2022 2021. September 30, 2022.

Note 3 - Balance Sheet Compon_2

Note 3 - Balance Sheet Components (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	September 30, 2022 December 31, 2021 Prepaid clinical trial costs (current portion) $ 1,231,337 $ - Prepaid insurance premiums 143,450 123,248 Prepaid rent 13,045 13,045 Other prepaid expenses 72,375 19,947 Total prepaid expenses $ 1,460,207 $ 156,240
Property, Plant and Equipment [Table Text Block]	September 30, 2022 December 31, 2021 Equipment and furnishings $ 725,812 $ 591,554 Leasehold improvements 115,605 115,605 Total property and equipment 841,417 707,159 Accumulated depreciation and amortization (592,434 ) (550,221 ) Total property and equipment, net $ 248,983 $ 156,938
Schedule of Other Assets [Table Text Block]	September 30, 2022 December 31, 2021 Prepaid clinical trial costs (noncurrent portion) $ 2,083,276 $ - Prepaid technology license fees 90,000 - Deposits 11,010 11,010 Total other assets $ 2,184,286 $ 11,010
Schedule of Accrued Liabilities [Table Text Block]	September 30, 2022 December 31, 2021 Accrued technology license fees – current portion $ 3,000,000 $ 3,000,000 Accrued compensation - 269,000 Other accrued expenses 709,984 108,826 Total accrued expenses $ 3,709,984 $ 3,377,826

Note 5 - Stockholders' Equity (

Note 5 - Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Warrant Description Number of Shares Exercise Price Expiration 2020 Warrants 120,000 $ 1.65 Jun 2025 2020 Unit Warrants 2,396,631 5.00 Sep 2025 2020 Representative Warrants 128,000 5.50 Mar 2024 2021 Representative Warrants 72,000 6.875 Aug 2024 2021 Warrants 100,000 13.00 Sep 2026 Jan 2022 Common Warrants 3,067,484 3.26 Feb 2027 May 2022 Preferred Investment Options 7,500,000 1.65 May 2028 Total Warrants Outstanding at September 30, 2022 13,384,115

Note 6 - Stock-based Compensa_2

Note 6 - Stock-based Compensation Expense (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended Sep. 30, Nine Months Ended Sep. 30, 2022 2021 2022 2021 Stock options: Research and development $ 54,293 $ 21,468 $ 162,878 $ 64,404 General and administrative 135,898 34,722 407,695 104,166 Total stock option expense 190,191 56,190 570,573 168,570 Stock awards (consultants): General and administrative 48,375 29,560 80,322 80,733 Total stock-based compensation expense $ 238,566 $ 85,750 $ 650,895 $ 249,303

Note 3 - Balance Sheet Compon_3

Note 3 - Balance Sheet Components (Details Textual) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Other Liabilities, Total	$ 2,000,000	$ 2,000,000

Note 3 - Balance Sheet Compon_4

Note 3 - Balance Sheet Components - Prepaid Expenses (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Prepaid clinical trial costs (current portion)	$ 1,231,337	$ 0
Prepaid insurance premiums	143,450	123,248
Prepaid rent	13,045	13,045
Other prepaid expenses	72,375	19,947
Total prepaid expenses	$ 1,460,207	$ 156,240

Note 3 - Balance Sheet Compon_5

Note 3 - Balance Sheet Components - Schedule of Property and Equipment (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Property and equipment, gross	$ 841,417	$ 707,159
Accumulated depreciation and amortization	(592,434)	(550,221)
Total property and equipment, net	248,983	156,938
Equipment and Furnishings [Member]
Property and equipment, gross	725,812	591,554
Leasehold Improvements [Member]
Property and equipment, gross	$ 115,605	$ 115,605

Note 3 - Balance Sheet Compon_6

Note 3 - Balance Sheet Components - Schedule Of Other Assets (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Prepaid clinical trial costs (noncurrent portion)	$ 2,083,276	$ 0
Prepaid technology license fees	90,000	0
Deposits	11,010	11,010
Total other assets	$ 2,184,286	$ 11,010

Note 3 - Balance Sheet Compon_7

Note 3 - Balance Sheet Components - Schedule of Accrued Expenses (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Accrued technology license fees – current portion	$ 3,000,000	$ 3,000,000
Accrued compensation	0	269,000
Other accrued expenses	709,984	108,826
Total accrued expenses	$ 3,709,984	$ 3,377,826

Note 4 - Commitments (Details T

Note 4 - Commitments (Details Textual)	3 Months Ended		9 Months Ended
	Sep. 30, 2022 USD ($) ft²	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) ft²	Sep. 30, 2021 USD ($)
Licensing Agreement, Future Minimum Payments Receivable, Current	$ 409,000		$ 409,000
Non-cancellable Obligations	1,200,000		1,200,000
Unrecorded Unconditional Purchase Obligation, Total	$ 612,000		$ 612,000
Office and Laboratory Lease Agreement [Member]
Area of Real Estate Property (Square Foot) | ft²	8,400		8,400
Operating Lease, Expense	$ 44,089	$ 42,803	$ 132,267	$ 128,410
Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year	$ 44,089		$ 44,089

Note 5 - Stockholders' Equity_2

Note 5 - Stockholders' Equity (Details Textual) - USD ($)			1 Months Ended			3 Months Ended	9 Months Ended
	May 27, 2022	Jan. 19, 2022	Aug. 31, 2022	Jul. 31, 2022	May 31, 2022	Mar. 31, 2021	Sep. 30, 2022	May 29, 2028
Stock Issued During Period, Value, New Issues						$ 9,408,920
Stock Incentive Plan 2020 [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)							1,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)							0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)							962,300
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)							$ 3.18
Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period (in shares)				75,000	68,500
Pre-Funded Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	11,071,214	2,360,000
Class of Warrant or Right, Exercised (in shares)	1,980,304
Common Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		3,067,484
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 3.26
Preferred Investment Options [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	12,121,214
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 1.65
Proceeds from Issuance or Sale of Equity, Total			$ 7,626,000
Class of Warrant or Right, Exercised (in shares)			4,621,214
Preferred Investment Options [Member] | Forecast [Member]
Class Of Warrant Or Rights, Amount Of Shares To Expire (in shares)								9,090,910
Stock Purchase Warrants [Member]
Warrants and Rights Outstanding, Term (Year)							8 years 7 months 6 days
Private Placement [Member]
Stock Issued During Period, Value, New Issues	$ 1,050,000	$ 707,484
Proceeds from Issuance or Sale of Equity, Total	$ 18,500,000	$ 9,200,000

Note 5 - Stockholders' Equity -

Note 5 - Stockholders' Equity - Schedule of Warrants (Details)	Sep. 30, 2022 $ / shares shares
Number of shares (in shares)	13,384,115
Warrants 2020 [Member]
Number of shares (in shares)	120,000
Exercise price (in dollars per share) | $ / shares	$ 1.65
Unit Warrants 2020 [Member]
Number of shares (in shares)	2,396,631
Exercise price (in dollars per share) | $ / shares	$ 5
Representative Warrants 2020 [Member]
Number of shares (in shares)	128,000
Exercise price (in dollars per share) | $ / shares	$ 5.50
Representative Warrants 2021 [Member]
Number of shares (in shares)	72,000
Exercise price (in dollars per share) | $ / shares	$ 6.875
Warrants 2021 [Member]
Number of shares (in shares)	100,000
Exercise price (in dollars per share) | $ / shares	$ 13
January 2022 Common Warrants [Member]
Number of shares (in shares)	3,067,484
Exercise price (in dollars per share) | $ / shares	$ 3.26
May 2022 Preferred Investment Options 1 [Member]
Number of shares (in shares)	7,500,000
Exercise price (in dollars per share) | $ / shares	$ 1.65

Note 6 - Stock-based Compensa_3

Note 6 - Stock-based Compensation Expense (Details Textual) - USD ($)	1 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2022
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount		$ 849,571
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)		1 year 8 months 12 days
Prepaid Expense, Value of Stock Issued for Services During Period		$ 72,375
Research and Development Expense [Member]
Warrant Issuance Expense	$ 209,825

Note 6 - Stock-Based Compensa_4

Note 6 - Stock-Based Compensation Expense - Schedule of Stock-Based Compensation Expense (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Total stock-based compensation expense	$ 238,566	$ 85,750	$ 650,895	$ 249,303
Share-Based Payment Arrangement, Option [Member]
Total stock-based compensation expense	190,191	56,190	570,573	168,570
Share-Based Payment Arrangement, Option [Member] | Research and Development Expense [Member]
Total stock-based compensation expense	54,293	21,468	162,878	64,404
Share-Based Payment Arrangement, Option [Member] | General and Administrative Expense [Member]
Total stock-based compensation expense	135,898	34,722	407,695	104,166
Restricted Stock [Member] | General and Administrative Expense [Member]
Total stock-based compensation expense	$ 48,375	$ 29,560	$ 80,322	$ 80,733

Note 7 - Net Loss Per Share (De

Note 7 - Net Loss Per Share (Details Textual) - shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	14,346,415	3,418,631